dr. long on the results of the pooled analysis of the combi-i trial in melanoma
Published 5 years ago • 146 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
1:46
dr. nathan on 5-year survival outcomes of combi-d and combi-v trials in braf v600-mutant melanoma
-
2:03
dr. finn discusses the pooled analysis of reach and reach-2 in hcc
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
2:11
dr. georgina long on dabrafenib and trametinib in braf-mutated melanoma
-
1:31
dr. warner discusses findings from combi-i trial in melanoma
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma
-
1:19
dr. robert on potential of dabrafenib/trametinib in melanoma brain metastases
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
1:22
dr. sznol discusses the combination of ipilimumab and nivolumab in melanoma
-
2:33
dr. sullivan discusses role of dabrafenib plus trametinib in melanoma
-
0:48
dr. long on including patients with melanoma who have brain mets on clinical trials
-
1:05
georgina long on treating melanoma with dabrafenib plus trametinib
-
2:11
dr. long on rationale for nivolumab/ipilimumab in patients with melanoma who have brain mets
-
1:05
dr. hodi on long-term follow-up of nivolumab in patients with melanoma
-
1:05
dr. weber on the future of checkpoint inhibitors in melanoma
-
1:31
dr long on unmet needs in braf-mutant melanoma
-
1:05
dr. weber on rationale for the checkmate-238 trial in melanoma
-
0:57
dr. postow on os results of checkmate-069 study
-
8:42
conclusion: improving outcomes in melanoma